capecitabine remains the adjuvant standard of care for tnbc with residual disease | ingrid mayer
Published 3 years ago • 2.7K plays • Length 4:01Download video MP4
Download video MP3
Similar videos
-
4:28
for residual tnbc post-chemo, capecitabine should be offered
-
21:36
treatment planning for triple negative breast cancer | 2022 evolution conference
-
30:56
adjuvant treatment for early stage hormone positive breast cancer: role of genomic signatures
-
4:42
results from adding adjuvant capecitabine to treatment for breast cancer patients
-
1:32
comparing data for capecitabine after neoadjuvant chemotherapy in tnbc
-
4:12
no boost in os with addition of capecitabine for early tnbc
-
2:17
atezolizumab with adjuvant chemotherapy for early-stage triple negative breast cancer
-
1:25
dr. goetz on adjuvant capecitabine following neoadjuvant chemotherapy and surgery
-
1:56
dr. thomas on adjuvant capecitabine/gemcitabine for ehcc and gbca
-
14:24
adjuvant capecitabine did not significantly improve outcomes for early-stage tnbc
-
10:56
debate: optimal adjuvant chemotherapy for resected pancreatic cancer - gemcitabine/capecitabine
-
2:28
comment: capecitabine for elderly early-stage breast cancer
-
5:41
future directions for treatment of tnbc
-
5:32
triple negative breast cancer treatment update: capecitabine, immunotherapy and platinum salts
-
1:27
what to do in patients with early-stage tnbc who have not achieved a pcr?
-
7:38
tucatinib plus trastuzumab & capecitabine for patients with her2-positive breast cancer & brain mets
-
5:00
olympia: adjuvant olaparib delays recurrence of brca-mutant breast cancer | judy garber
-
3:27
tesetaxel plus capecitabine for patients with metastatic breast cancer
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer